Guardant Health announces positive results from pivotal ECLIPSE study evaluating a blood test for the detection of colorectal cancer
Study demonstrates 83% sensitivity for detection of colorectal cancer with specificity of 90%
New ECLIPSE study validates the accuracy of Shield. See the data
Study demonstrates 83% sensitivity for detection of colorectal cancer with specificity of 90%